Latest Pre-exposure prophylaxis Stories
In the heart of the global AIDS epidemic, a breakthrough has been discovered in preventing the HIV virus from being transmitted among heterosexual couples.
In a result that will fundamentally change approaches to HIV prevention in Africa, an international study has demonstrated that individuals at high risk for HIV infection who took a daily tablet containing an HIV medication â€“ either the antiretroviral medication tenofovir or tenofovir in combination with emtricitabine â€“ experienced significantly fewer HIV infections than those who received a placebo pill.
Today, researchers from two major HIV prevention trials announced favorable results of an approach called oral pre-exposure prophylaxis, or PrEP.
NEW YORK, July 13, 2011 /PRNewswire-USNewswire/ -- Results from two African studies of pre-exposure prophylaxis, or PrEP, released today provide clear evidence that the antiretroviral drugs used to treat HIV can also be used to prevent HIV among heterosexual men and women at risk of HIV infection.
In a recent clinical trial, nonâ€“HIV-infected individuals who used the antiretroviral drug Truvada on a daily basis cut their risk of becoming infected with HIV by 44 percent.
A new study from the University of North Carolina at Chapel Hill School of Medicine further validates the use of humanized BLT mice in the fight to block HIV transmission.
Argues AIDS vaccine research is a key part of the HIV prevention revolution NEW YORK, May 18, 2011 /PRNewswire-USNewswire/ -- This year HIV Vaccine Awareness Day comes at the dawn of a true prevention revolution that could finally turn the tide of the AIDS epidemic.
The first human studies of an oral drug regimen to prevent HIV infection in high-risk individuals yielded a promising near 50% reduction in HIV incidence, but a number of issues require additional research before oral pre-exposure prophylaxis (PrEP) can be implemented on a large scale.
In the first study to make head-to-head comparisons between tenofovir gel and oral tenofovir â€“ two promising approaches for preventing HIV in women â€“ researchers found that daily use of the vaginal gel achieved a more than 100-times higher concentration of active drug in vaginal tissue than did the oral tablet, while, compared to the gel, the tablet used daily was associated with a 20-times higher active drug concentration in blood.
A gel developed to protect against HIV during vaginal sex produced a strong antiviral effect when used in the rectum.